A clinical study of Trifarotene Cream in Adults and Adolescents with With Lamellar Ichthyosis

Phase 1

Conditions: amellar ichthyosis (LI)Autosomal Recessive Ichthyosis with Lamellar Scale
MedDRA version: 20.0Level: LLTClassification code 10023686Term: Lamellar ichthyosisSystem Organ Class: 100000004850
Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]

Registration Number: EUCTR2018-003272-12-GB

Lead Sponsor: Mayne Pharma LLC

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Authorised-recruitment may be ongoing or finished

Sex: All

Target Recruitment: 120

Inclusion Criteria

1. For Cohort A: subject is =18 years old; for Cohort B: subject is =12 years old.
2. Subject has known diagnosis of LI.
3. Subject has moderate to severe (IGA 3-4) LI on the IGA of LI severity
4. Subject has signed an ICF at Screening before any investigational procedures.
Subjects <18 years of age (or Age of Majority) must sign an assent form in conjunction with an ICF signed by the parent/legal representative.
5. Subject who is participating in photography has signed a photography ICF.
6. Subject who is participating in the optional PK substudy has signed a PK ICF.
7. Subject is not of childbearing potential, i.e., a female who has not yet begun menstruating or who is postmenopausal (absence of menstrual bleeding for 1 year oophorectomy),
OR
Subject is a woman of childbearing potential (WOCBP) or a male subject with sexual partners capable of reproduction who agrees to use 2 effective forms of contraception during the study and for at least 1 month after the last study drug application. The 2 authorized forms of contraception are condom used with 1 of the following methods of contraception:
• bilateral tubal ligation
• combined oral contraceptives (estrogens and progesterone) or implanted or injectable contraceptives with a stable dose for at least 1 month before Baseline; hormonal contraceptives must inhibit ovulation
• hormonal intrauterine device (IUD) inserted at least 1 month before Baseline
OR
Agrees to abstain from heterosexual intercourse during study participation and for 1 month after the last application of study drug and to use a highly effective contraceptive as backup if he or she becomes sexually active during the study. Abstinence is only acceptable if this is the subject’s usual lifestyle. Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method are not acceptable methods of contraception.
AND
Male subjects may not donate sperm during the study and for at least 1 month after the last study drug application.
Note: Subjects who are premenstrual at Screening but begin menses during the study should follow the pregnancy testing schedule for WOCBP and must abstain from sexual intercourse while in the study and for at least 1 month after the last study drug application.
8. Women of child-bearing potential must be nonlactating and have negative pregnancy test results at Screening (serum) and on Day 1 before study drug administration (urine).
9. Subject is reliable and capable of adhering to the protocol and visit schedule, in the investigator’s judgment, and has signed informed consent/assent, as applicable.
10. Subject is taking no more than 3500 IU/day Vitamin A (e.g., as in a multivitamin).
Are the trial subjects under 18? yes
Number of subjects for this age range: 40
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 70
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10

Exclusion Criteria

1. Subject has any variant of ichthyosis other than LI or another disorder of keratinization including syndromic ichthyoses.
2. Subject has current moderate or severe stinging/burning at Screening.
3. Subject has an ongoing cutaneous infection or any other significant concomitant skin disease (other than the LI) which, in the investigator’s opinion, may interfere with the study assessments.
4. Subject with a known lipid disorder (hypertriglyceridemia >200 mg/dL, hypercholesterolemia >250 mg/dL) unless well controlled by stable doses of lipid-lowering agents for at least 6 months.
5. Subject was previously treated with trifarotene/CD5789, in an acne or ichthyosis study.
6. Subject has any other significant concomitant disease, or poorly controlled medical condition other than LI that in the investigator’s opinion may put him or her at risk if he or she takes part in the study, and/or that may interfere with the study assessments.
7. Subject has a medical condition that potentially alters bone metabolism (e.g., osteoporosis, thyroid dysfunction, Cushing syndrome, Crohn’s disease, or ulcerative colitis).
8. Subject is being treated for major depression disorder and/or has a history of major depression or suicide attempt requiring hospitalization, medications, and close psychiatric surveillance to prevent suicide attempts.
9. Subject with positive serology for hepatitis B surface antigen, hepatitis C, or are known to be HIV positive or to have AIDS at Screening.
10. Subject with any of the following laboratory values at Screening:
a. Aspartate aminotransferase or alanine aminotransferase >1.5 × upper limit of normal defined by the laboratory
b. Total bilirubin >1.1 mg/dL or, in case of Gilbert’s syndrome, total bilirubin >3 mg/dL
c. Hemoglobin <12.5 g/dL for men and <11.5 g/dL for women
d. Platelets <150 × 109/L or >400 × 109/L.
11. Subject has any clinically other significant abnormal laboratory value (hematology,chemistry, or urinalysis) at Screening that, in the investigator’s opinion, may put the subject at risk if he or she takes part in the study, and/or that may interfere with the study assessments.
12.Subject has had recent systemic malignancy (e.g., within 5 years) with exception of nonmelanoma skin cancer or cervical intraepithelial neoplasia of Grade 1 who are >6 months post-treatment
13. Subject has a history of long QT syndrome or clinically significant electrocardiogram (ECG) abnormalities, including clinically significant conduction disorders or significant arrhythmias, QTcF interval >450 ms, PR interval is not between 120 and 220 ms (inclusive), HR >100 bpm or <50 bpm, QRS interval >110 ms, or QT intervals that cannot be consistently analyzed.
14. Subject has a known allergy or sensitivity to any of the components of the investigational products.
15. Subject has been exposed to excessive ultraviolet (UV) radiations on the treated zones within 1 month before Baseline visit or who is planning intensive UV exposure during the study (e.g., occupational exposure to the sun, sunbathing, phototherapy, etc.).
16. Subject is inherently sensitive to sunlight.
17.Subject is unable or unwilling to stop use of topical or systemic retinoids
18. Subject is presumed to be abusing drugs or alcohol at Screening or Baseline Visits based on medical history or current clinical symptoms.
19. Subject is participating in another interventional clinical trial.
20. Subject is institutionalized
21.Subject is in any way relat

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials